Cited by 1,521HIV-related health complications and treatmentsHIV/AIDS drug development and treatmentLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Open access

The DAD Study Group·2007·New England Journal of Medicine

DOI 10.1056/nejmoa062744

Open this paper in CoChat — free account

Abstract

BACKGROUND: We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs according to the class of antiretroviral drugs. We conducted a study to investigate the association of cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction. METHODS: We analyzed data collected through February 2005 from our prospective observational study of 23,437 patients infected with the human immunodeficiency virus. The incidence rates of myocardial infarction during the follow-up period were calculated, and the associations between myocardial infarction and exposure to protease inhibitors or nonnucleoside reverse-transcriptase inhibitors were determined. RESULTS: Three hundred forty-five patients had a myocardial infarction during 94,469 person-years of observation. The incidence of myocardial infarction increased from 1.53 per 1000 person-years in those not exposed to protease inhibitors to 6.01 per 1000 person-years in those exposed to protease inhibitors for more than 6 years. After adjustment for exposure to the other drug class and established cardiovascular risk factors (excluding lipid levels), the relative rate of myocardial infarction per year of protease-inhibitor exposure was 1.16 (95% confidence interval [CI], 1.10 to 1.23), whereas the relative rate per year of exposure to nonnucleoside reverse-transcriptase inhibitors was 1.05 (95% CI, 0.98 to 1.13). Adjustment for serum lipid levels further reduced the effect of exposure to each drug class to 1.10 (95% CI, 1.04 to 1.18) and 1.00 (95% CI, 0.93 to 1.09), respectively. CONCLUSIONS: Increased exposure to protease inhibitors is associated with an increased risk of myocardial infarction, which is partly explained by dyslipidemia. We found no evidence of such an association for nonnucleoside reverse-transcriptase inhibitors; however, the number of person-years of observation for exposure to this class of drug was less than that for exposure to protease inhibitors.

Integrity signals

Registry

Crossref · 10.1056/nejmoa062744

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,393
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
CD4+ Count–Guided Interruption of Antiretroviral Treatment
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,250
Self-citation
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
El-Sadr, W. M., & The Data Collection On Adverse Events Of Anti-HIV Drugs (DAD) Study Group (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,677
Self-citation
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V., Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A. N., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,269
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
Friis‐Møller, N., Weber, R. K., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M. G., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,076
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski, S., Morales-Ramirez, J. O., Tashima, K. T., Rachlis, A., Skiest, D. J., Stanford, J., Stryker, R., Johnson, P. C., Labriola, D., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B. J., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
Grünfeld, C., Pang, M., Doerrler, W. T., Shigenaga, J. K., Jensen, P., & Feingold, K. R. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.5.1373735 · Cited by 845
Impact of HIV infection and HAART on serum lipids in men
Riddler, S. A. (2003) · JAMA · doi:10.1001/jama.289.22.2978 · Cited by 624

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 3

10.1210/jc.74.5.1045 · DOI
Phillips AN, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 26, 2007. abstract. (Accessed March 29, 2007, athttp://www.retroconference.org/2007/abstracts/28863.htm.)
Sabin C, Morfeldt L, Friis-Møller N, et al. Changes over time in antiretroviral therapy (ART) use and risk factors for cardiovascular disease (CVD) in the D:A:D study. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 25, 2005. abstract. (Accessed March 29, 2007, athttp://www.retroconference.org/2005/cd/abstracts/25243.htm.)

Sorted by citations

Items 701–800 of 999

HIV-associated psoriasis
Queirós, N., & Torres, T. R. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2018.02.020 · Cited by 17
Diagnosis, risk factors and management of diabetes mellitus in HIV-infected persons in France: A real-life setting study
Kousignian, I., Sautereau, A., Vigouroux, C., Cros, A., Kretz, S., Viard, J., & Slama, L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250676 · Cited by 15
Cardiovascular risks associated with protease inhibitors for the treatment of HIV
Hatleberg, C. I., Ryom, L., & Sabin, C. A. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1935863 · Cited by 17
Vitamin D Deficiency is Associated with the Development of Subclinical Coronary Artery Disease in African Americans with HIV Infection: A Preliminary Study
Lai, H. C., Detrick, B., Fishman, E. K., Gerstenblith, G., Brinker, J., Hollis, B. W., Bartlett, J. A., Cofrancesco, J., Tong, W., Tai, H., et al. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318250bf99 · Cited by 17
Cardiovascular Complications in Children with HIV Infection
Sims, A., & Hadigan, C. M. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0081-9 · Cited by 17
Vitamin D deficiency in HIV-infected individuals: one more risk factor for bone loss and cardiovascular disease?
Conrado, T., Miranda-Filho, D. D. B., & Bandeira, F. A. F. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000200006 · Cited by 17
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)
Menzaghi, B., Ricci, E. D., Carenzi, L., Parruti, G., Orofino, G., Guastavigna, M., Madeddu, G., Maggi, P., Biagio, A. D., Corsi, P., et al. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.12.005 · Cited by 17
Differential Effects of Rosiglitazone and Metformin on Postprandial Lipemia in Patients With HIV-Lipodystrophy
van Wijk, J. P. H., Hoepelman, A. I. M., de Koning, E. J. P., Dallinga‐Thie, G. M., Rabelink, T. J., & Cabezas, M. C. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.216192 · Cited by 17
The Framingham function overestimates the risk of ischemic heart disease in HIV-infected patients from Barcelona
Herrera, S., Guelar, A., Sorlí, L., Vila, J., Molas, E., Grau, M., Marrugat, J., Esteve, E., Güerri‐Fernández, R., Montero, M., et al. (2016) · HIV Clinical Trials · doi:10.1080/15284336.2016.1177266 · Cited by 17
Adverse drug reactions to antiretroviral medication
Roca, B. (2009) · Frontiers in bioscience · doi:10.2741/3340 · Cited by 17
Antiretroviral Drugs and the Risk of Myocardial Infarction
Kaplan, R. C., Tien, P. C., & Lazar, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071419 · Cited by 17
Patterns and predictors of cigarette smoking among HIV-infected patients in northern Nigeria
Iliyasu, Z., Gajida, A. U., Abubakar, I. S., Shittu, O. S., Babashani, M., & Aliyu, M. H. (2012) · International Journal of STD & AIDS · doi:10.1258/ijsa.2012.012001 · Cited by 16
Human Immunodeficiency Virus Infection–Related Heart Disease
Pham, T. V., & Torres, M. (2015) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2015.04.009 · Cited by 16
Circulating endothelial progenitor cells in HIV infection: A systematic review
Costiniuk, C. T., Hibbert, B. M., Simard, T., Ghazawi, F. M., Angel, J. B., & O’Brien, E. R. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.12.002 · Cited by 16
Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities
Guaraldi, G., & Baraboutis, I. G. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp240 · Cited by 16
Association of increased CD8 + and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting
Schneider, S., Spinner, C. D., Cassese, S., Promny, D., Hapfelmeier, A., Byrne, R. A., Baumann, M., Jäger, H., Steinlechner, E., Laugwitz, K., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001063 · Cited by 17
Monocyte Activation, but not Microbial Translocation, Is Independently Associated With Markers of Endovascular Dysfunction in HIV-Infected Patients Receiving cART
Pedersen, K. K., Manner, I. W., Seljeflot, I., Kvale, D., Os, I., Gerstoft, J., Nielsen, S. D., & Trøseid, M. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000339 · Cited by 16
Metabolic Syndrome in HIV/HCV Co-infected Patients
Collins, L. F., Adekunle, R. O., & Cartwright, E. J. (2019) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-019-00207-3 · Cited by 15
Pharmacokinetic Parameters of HIV‐1 Protease Inhibitors
do Nascimento, A. L. C. S., Fernandes, R. P., Quijia, C. R., Araújo, V. H. S., Pereira, J., Garcia, J. S., Trevisan, M. G., & Chorilli, M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000101 · Cited by 16
Sexual evaluation and treatment of ageing males with haemophilia
Bar-Chama, N. C., SNYDER, S., & Aledort, L. M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02507.x · Cited by 16
Morbidity and Mortality According to Latest CD4+ Cell Count among HIV Positive Individuals in South Africa Who Enrolled in Project Phidisa
Maduna, P. H., Dolan, M., Kondlo, L., Mabuza, H., Dlamini, J. N., Polis, M., Mnisi, T., Orsega, S., Maja, P., Ledwaba, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121843 · Cited by 16
Possible Biomarkers for the Early Detection of HIV-associated Heart Diseases: A Proteomics and Bioinformatics Prediction
Rasheed, S., Hashim, R., & Yan, J. S. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.02.001 · Cited by 16
Risk of Deaths, AIDS-Defining and Non-AIDS Defining Events among Ghanaians on Long-Term Combination Antiretroviral Therapy
Sarfo, F. S., Sarfo, M. A., Norman, B., Phillips, R. O., Bedu‐Addo, G., & Chadwick, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111400 · Cited by 16
Antiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studies
Friis‐Møller, N., Smieja, M., & Klein, D. B. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3282fb7bcf · Cited by 16
Non-Calcified Coronary Plaque Volume Inversely Related to Cd4 + T-Cell Count in HIV Infection
Duarte, H. A., Matta, J. R., Muldoon, N., Masur, H., Hadigan, C. M., & Gharib, A. M. (2011) · Antiviral Therapy · doi:10.3851/imp1994 · Cited by 16
A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk
Masiá, M., Bernal, E., Padilla, S., García, N., Escribano, J. C., Martínez, E., & Gutiérrez, F. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp250 · Cited by 16
General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases)
Sterling, T. R., & Chaisson, R. E. (2015) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-1-4557-4801-3.00124-7 · Cited by 16
Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia
Višković, K., Lepej, S. Ž., Gorenec, A., Grgić, I., Lukas, D., Zekan, Š., Dragobratović, A., Trupković, M., & Begovać, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-24446-4 · Cited by 16
Subclinical cardiovascular disease in HIV controller and long‐term nonprogressor populations
Brusca, R., Hanna, D. B., Wada, N., Blankson, J., Witt, M., Jacobson, L. P., Kingsley, L., Palella, F., Budoff, M. J., Brown, T. T., et al. (2019) · HIV Medicine · doi:10.1111/hiv.12820 · Cited by 16
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection
Calza, L., Verucchi, G., Pocaterra, D., Pavoni, M., Alfieri, A., Cicognani, A., Manfredi, R., Serra, C., & Chiodo, F. (2009) · International Journal of STD & AIDS · doi:10.1258/ijsa.2009.008504 · Cited by 16
suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART
Andersen, O., Eugen‐Olsen, J., Kofoed, K., Iversen, J., & Haugaard, S. B. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.01.014 · Cited by 16
Cardiovascular Abnormalities in HIV-Infected Individuals
Fisher, S. D., & Lipshultz, S. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00072-x · Cited by 16
Inflammatory and immune markers in HIV ‐infected older adults on long‐term antiretroviral therapy: Persistent elevation of sCD14 and of proinflammatory effector memory T cells
Watanabe, M., Jergović, M., Davidson, L., LaFleur, B., Castaneda, Y., Martinez, C., Smithey, M. J., Stowe, R. P., Haddad, E. K., & Nikolich‐Žugich, J. (2022) · Aging Cell · doi:10.1111/acel.13681 · Cited by 15
Association Between the Development of Subclinical Cardiovascular Disease and Human Immunodeficiency Virus (HIV) Reservoir Markers in People With HIV on Suppressive Antiretroviral Therapy
Turcotte, I., Far, M. E., Sadouni, M., Chartrand‐Lefebvre, C., Filali‐Mouhim, A., Fromentin, R., Chamberland, A., Jenabian, M.-A., Baril, J.-G., Trottier, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac874 · Cited by 15
Cardiovascular Disease Risk Factor Control in People With and Without HIV
Silverberg, M. J., Levine, T., Lea, A. N., Williams, A. E., Alexeeff, S., BRYANT, K. J., Cavassini, M. L., Flamm, J., Hare, C. B., Ingle, S. M., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciad728 · Cited by 15
Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults
Ferrer, E., del Río, L., Martínez, E., Curto, J., Domingo, P., Ribera, E., Negredo, E., Rosales, J., Saumoy, M., Ordóñez‐Llanos, J., et al. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0254 · Cited by 15
Vitamin D insufficiency and subclinical atherosclerosis in non‐diabetic males living with HIV
Portilla, J., Moreno, Ó., Serna‐Candel, C., Escoín, C., Alfayate, R., Reus, S., Merino, E., Boix, V., Giner, L., Sánchez–Payá, J., et al. (2014) · Journal of the International AIDS Society · doi:10.7448/ias.17.1.18945 · Cited by 15
Alcohol and Race/Ethnicity Elicit Different Changes in Lipid Profiles in HIV-Infected Individuals Receiving Highly Active Antiretroviral Therapy
Míguez‐Burbano, M. J., Lewis, J. E., & Malow, R. M. (2009) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/j.jana.2009.02.004 · Cited by 15
The Roles of Genetic Polymorphisms and Human Immunodeficiency Virus Infection in Lipid Metabolism
de Almeida, E. R. D., Reiche, E. M. V., Kallaur, A. P., Flauzino, T., & Watanabe, M. A. E. (2013) · BioMed Research International · doi:10.1155/2013/836790 · Cited by 16
Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy
Anuurad, E., Thomas-Geevarghese, A., Devaraj, S., Albu, J., Minolfo, R., El-Sadr, W. M., Lu, G., Karmally, W., & Berglund, L. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.042 · Cited by 15
Some patient-related factors associated with late access to ART in China's free ART program
Wen, Y. F., Zhao, D., Dou, Z., Ma, Y., Zhao, Y., Lü, L., Liu, W., Zhu, H., & Zhang, F. (2011) · AIDS Care · doi:10.1080/09540121.2011.555748 · Cited by 15
The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges
Ahmed, M. H., Al‐Atta, A., & Hamad, M. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.706604 · Cited by 15
Impact of HIV infection on cardiac deformation
Mendes, L., Silva, D., Miranda, C., Sá, J., Duque, L., Duarte, N., de Brito, P. M., Bernardino, L., & Poças, J. (2014) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2013.12.006 · Cited by 15
Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV‐1‐infected patients treated with abacavir
Kowalska, J. D., Kirk, O., Mocroft, A., Høj, L., Friis‐Møller, N., Reiss, P., Weller, I. V. D., & Lundgren, J. D. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00763.x · Cited by 15
Hipertensión arterial, infección por el virus de la inmunodeficiencia humana y tratamiento antirretrovírico de gran actividad
Bernardino, J. I., Zamora, F. X., Montes, M., Puig, J. G., & Arribas, J. R. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2008.07.005 · Cited by 15
Cardiopatía isquémica en el VIH: profundizando en el conocimiento del riesgo cardiovascular
Raposeiras‐Roubín, S., & Triant, V. A. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.08.035 · Cited by 16
Approaches to Improve the Surveillance, Monitoring, and Management of Noncommunicable Diseases in HIV-Infected Persons: Viewpoint
Patel, P., Sabin, K. M., & Godfrey‐Faussett, P. (2018) · JMIR Public Health and Surveillance · doi:10.2196/10989 · Cited by 15
Coronary artery disease in patients with human immunodeficiency virus infection
Mondal, P., Aljizeeri, A. H., Small, G. R., Malhotra, S., Harikrishnan, P., Affandi, J. S., Buechel, R. R., Dwivedi, G., Al-Mallah, M. H., & Jain, D. (2020) · Journal of Nuclear Cardiology · doi:10.1007/s12350-020-02280-4 · Cited by 15
Coronary Artery Disease–Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study
Schoepf, I. C., Thorball, C. W., Ledergerber, B., Engel, T., Raffenberg, M., Kootstra, N. A., Reiss, P., Hasse, B. K., Marzolini, C., Thurnheer, C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab521 · Cited by 15
Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects
Carosi, G., Lazzarin, A., Stellbrink, H., Moyle, G. J., Rugină, S., Staszewski, S., Givens, N., Ross, L., Granier, C., Ait‐Khaled, M., et al. (2009) · HIV Clinical Trials · doi:10.1310/hct1006-356 · Cited by 15
Cerebrovascular events in HIV-infected patients: an analysis of a cohort of 3203 HIV+ patients during the times of cART
Arentzen, M., Jubt, F., Evers, S., Heßelmann, V., Fiori, W., Reichelt, D., Oelker-Grueneberg, U., Schwindt, W., Dziewas, R., & Husstedt, I. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.956870 · Cited by 15
Predicting smoking cessation and its relapse in HIV ‐infected patients: the S wiss HIV C ohort S tudy
Schäfer, J., Young, J., Bernasconi, E., Ledergerber, B., Nicca, D., Calmy, A., Cavassini, M. L., Furrer, H., Battegay, M., Bucher, H. C., et al. (2014) · HIV Medicine · doi:10.1111/hiv.12165 · Cited by 15
Longitudinal Changes in Body Composition by Dual-energy Radiograph Absorptiometry Among Perinatally HIV-infected and HIV-uninfected Youth
Sharma, T. S., Somarriba, G. A., Arheart, K. L., Neri, D. A., Mathew, M. S., Graham, P. L., Scott, G. B., & Miller, T. L. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001963 · Cited by 15
Gender differences in the use of cardiovascular interventions in HIV ‐positive persons; the D:A:D Study
Hatleberg, C. I., Ryom, L., El-Sadr, W. M., Mocroft, A., Reiss, P., Wit, S. D., Dabis, F., Pradier, C., Monforte, A. D., Kovari, H., et al. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25083 · Cited by 15
Self-citation
HIV treatment is associated with a twofold higher probability of raised triglycerides: pooled analyses in 21 023 individuals in sub-Saharan Africa
Ekoru, K., Young, E. H., Dillon, D., Gurdasani, D., Stehouwer, N. R., Faurholt‐Jepsen, D., Levitt, N. S., Crowther, N. J., Nyirenda, M., Njelekela, M. A., et al. (2018) · Global Health · doi:10.1017/gheg.2018.7 · Cited by 16
Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study
Demontès, M., Eymard‐Duvernay, S., Allavena, C., Jovelin, T., Reynes, J., Hentzien, M., Ravaux, I., Delobel, P., Brégigeon, S., Rey, D., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1171 · Cited by 16
Improvement in lipid profiles over 6 years of follow‐up in adults with AIDS and immune reconstitution
Williams, P. L., Wu, J. W., Cohn, S. E., Koletar, S. L., McCutchan, J. A., Murphy, R. L., & Currier, J. S. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00685.x · Cited by 15
Morbidity and mortality in ageing HIV ‐infected haemophilia patients
van de Putte, D. E. F., Fischer, K., Roosendaal, G., Hoepelman, A. I. M., & Mauser‐Bunschoten, E. P. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02912.x · Cited by 15
Immunotherapies in HIV-1 infection
Pett, S. L. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328329d090 · Cited by 15
Conventional cardiovascular risk factors in HIV infection: how conventional are they?
Sabin, C. A., & Worm, S. W. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3282f6a613 · Cited by 15
Changes in Lipids and Lipoprotein Particle Concentrations After Interruption of Antiretroviral Therapy
Lampe, F. C., Duprez, D. A., Kuller, L. H., Tracy, R. P., Otvos, J. D., Stroes, E. S. G., Cooper, D. A., Hoy, J., Paton, N., Friis‐Møller, N., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181d32158 · Cited by 15
High-risk coronary plaque, invasive coronary procedures, and cardiac events among HIV-positive individuals and matched controls
Nadel, J., O’Dwyer, E., Emmanuel, S., Huang, J., Cheruvu, S., SAMMEL, N. L., Brew, B. J., Otton, J. M., & Holloway, C. J. (2016) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2016.07.018 · Cited by 15
Cardiovascular disease in human immunodeficiency virus
Cheruvu, S., & Holloway, C. J. (2014) · Internal Medicine Journal · doi:10.1111/imj.12381 · Cited by 14
A 39-Year-Old Man With HIV-Associated Lipodystrophy
Fuller, J. (2008) · JAMA · doi:10.1001/jama.300.5.jrr80007 · Cited by 14
Incidence of primary hypertension in a population–based cohort of HIV–infected compared with non–HIV–infected persons and the effect of combined antiretroviral therapy
Tripathi, A., Jerrell, J. M., Skelton, T. N., Nickels, M. A., & Duffus, W. A. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.01.007 · Cited by 14
Challenges in treating elderly patients with haemophilia: A focus on cardiology
Zimmermann, R., Staritz, P., & Huth‐Kühne, A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2013.10.023 · Cited by 14
Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation
Morieri, M. L., Guardigni, V., Sanz, J. M., Nora, E. D., Soavi, C., Zuliani, G., Sighinolfi, L., & Passaro, A. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-017-2925-4 · Cited by 14
Diagnosis and Management of Dyslipidemia
Myerson, M. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-10451-1_3 · Cited by 14
Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy
Mizushima, D., Dung, N. T. H., Dung, N. T., Matsumoto, S., Tanuma, J., Gatanaga, H., Trung, N. V., Kính, N. V., & Oka, S. (2020) · Global Health & Medicine · doi:10.35772/ghm.2019.01035 · Cited by 14
Cardiovascular disease and prevention among people living with HIV in South Florida
Pyarali, F. F., Iordanov, R. B., Ebner, B., Grant, J. K., Vincent, L. T., Toirac, A., Haque, T., Zablah, G. J., Kapoor, K., Powell, A. R., et al. (2021) · Medicine · doi:10.1097/md.0000000000026631 · Cited by 14
Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans
The Korean Society for AIDS (2011) · Infection and Chemotherapy · doi:10.3947/ic.2011.43.2.89 · Cited by 14
Heart Rate Variability and Heart Rate Turbulence in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy
Wongcharoen, W., Khienprasit, K., Phrommintikul, A., Sukonthasarn, A., & Chattipakorn, N. (2013) · Annals of Noninvasive Electrocardiology · doi:10.1111/anec.12064 · Cited by 14
Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy
Resino, S., Micheloud, D., Lorente, R., Bellón, J., Navarro, M. L. M., & Muñoz‐Fernández, M. Á. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2010.00837.x · Cited by 14
Relationship between cytomegalovirus infection and procoagulant changes in human immunodeficiency virus‐infected patients
Mulder, R., Tichelaar, Y. I. G. V., Sprenger, H. G., Mulder, A. B., & Lijfering, W. M. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03415.x · Cited by 14
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir
Martínez, E., d’Albuquerque, P. M., Pérez, I., Pich, J., & Gatell, J. M. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0150 · Cited by 14
Association of Clinical and Therapeutic Factors with Incident Dyslipidemia in a Cohort of Human Immunodeficiency Virus–Infected and Non-Infected Adults: 1994–2011
Tripathi, A., Jerrell, J. M., Liese, A. D., Zhang, J., Rizvi, A. A., Albrecht, H., & Duffus, W. A. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2013.0017 · Cited by 14
Aspects actuels de la cryptococcose neuroméningée chez des sujets adultes infectés par le VIH dans le service de médecine interne du CHU de Treichville d’Abidjan (Côte d’Ivoire)
Kadjo, K., Ouattara, B., Adoubryn, K. D., Kra, O., & Niamkey, E. (2011) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2010.11.007 · Cited by 14
Renal Impairment Is Associated With Coronary Heart Disease in HIV-Positive Men
Campbell, L. J., Desai, M., Hegazi, A., Ibrahim, F., Melikian, N., Hay, P., Fox, J., & Post, F. A. (2012) · HIV Clinical Trials · doi:10.1310/hct1306-343 · Cited by 14
HIV-associated kidney disease in the context of an aging population
Naftalin, C. M., Nathan, B., Hamzah, L., & Post, F. A. (2011) · Sexual Health · doi:10.1071/sh10146 · Cited by 14
Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy
Study, S. H. C., Bucher, H. C., Rickenbach, M., Young, J., Glass, T. R., Vallet, Y., Bernasconi, E., Cavassini, M. L., Fux, C. A., Schiffer, V., et al. (2010) · Antiviral Therapy · doi:10.3851/imp1475 · Cited by 14
Incipient Renal Impairment as a Predictor of Subclinical Atherosclerosis in HIV-Infected Patients
Villar, S. S., Estrada, V., Gómez‐Garré, D., Ávila, M., Fuentes, M. E., Sánchez-Parra, C., Sainz, T., Patiño, R., & Fernández‐Cruz, A. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182414366 · Cited by 14
The prevalence of HIV in the sudden, unexplained and unexpected death population at the Pretoria Medico-Legal Laboratory
Morris, N., du Toit‐Prinsloo, L., Webber, L. M., & Saayman, G. (2016) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v17i1.424 · Cited by 14
Cardiovascular Risk in HIV-Infected and Uninfected Postmenopausal Minority Women: Use of the Framingham Risk Score
Cortés, Y. I., Reame, N. K., Zeana, C. B., Jia, H., Ferris, D. C., Shane, E. J., & Yin, M. T. (2016) · Journal of Women s Health · doi:10.1089/jwh.2015.5736 · Cited by 14
Ischemic Heart Disease in HIV: An In-depth Look at Cardiovascular Risk
Raposeiras‐Roubín, S., & Triant, V. A. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.10.005 · Cited by 14
Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services
Ahmed, M. H., Woodward, C., & Mital, D. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000128 · Cited by 14
VCAM-1 as a Biomarker of Endothelial Function among HIV-Infected Patients Receiving and Not Receiving Antiretroviral Therapy
Lembas, A., Zawartko, K., Sapuła, M., Mikuła, T., Kozłowska, J., & Wiercińska‐Drapało, A. (2022) · Viruses · doi:10.3390/v14030578 · Cited by 14
Higher Plasma Myeloperoxidase Levels Are Not Associated with an Increased Risk for Cardiovascular Events in HIV-Infected Adults
El‐Bejjani, D., Hazen, S. L., Mackay, W., Glass, N. E., Hulgan, T., Tungsiripat, M., & McComsey, G. A. (2008) · HIV Clinical Trials · doi:10.1310/hct0903-207 · Cited by 14
The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz
Mahungu, T. W., Nair, D. R., Smith, C. J., Egan, D., Youle, M. S., Johnson, M. A., Khoo, S., Back, D., & Owen, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.78 · Cited by 14
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
Smith, E. D., Malvestutto, C., Ribaudo, H. J., Fichtenbaum, C. J., Aberg, J. A., Watanabe, M., Bloomfield, G. S., Currier, J. S., Chu, S. M., Fitch, K. V., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf177 · Cited by 13
Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals
Hatleberg, C. I., Ryom, L., El-Sadr, W. M., Smith, C. J., Weber, R. K., Reiss, P., Fontas, É., Dabis, F., Law, M. G., Monforte, A. D., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001076 · Cited by 13
Direct and indirect cardiovascular and cardiometabolic sequelae of the combined anti-retroviral therapy on people living with HIV
Batta, Y., King, C., Cooper, F., Johnson, J. L., Haddad, N., Boueri, M. G., DeBerry, E., & Haddad, G. E. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1118653 · Cited by 17
Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV
Mazzitelli, M., Sasset, L., Gardin, S., Leoni, D., Trunfio, M., Scaglione, V., Mengato, D., Agostini, E., Vania, E., Putaggio, C., et al. (2023) · Viruses · doi:10.3390/v15081740 · Cited by 13
Hepatitis C, human immunodeficiency virus and metabolic syndrome: interactions
Kotler, D. P. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01951.x · Cited by 13
Ankle Brachial Index Screening for Occult Vascular Disease Is Not Useful in HIV-Positive Patients
Johns, K., Saeedi, R., Mancini, G. B. J., & Bondy, G. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2009.0275 · Cited by 13
Contributions of HIV-1 Nef to immune dysregulation in HIV-infected patients: a therapeutic target?
Witkowski, W., & Verhasselt, B. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.830712 · Cited by 14
Cause of death in HIV-infected patients in South Carolina (2005–2013)
Cima, M., Parker, D. R., Ahmed, Y. A., Cook, S., Dykema, S., Dukes, K., Albrecht, S., & Weissman, S. (2015) · International Journal of STD & AIDS · doi:10.1177/0956462415571970 · Cited by 13
A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection
Mauskopf, J., Annemans, L., Hill, A. M., & SMETS, E. F. (2010) · PharmacoEconomics · doi:10.2165/11587410-000000000-00000 · Cited by 13
Antiretroviral molecules and cardiovascular diseases.
Gibellini, D., Borderi, M., Clò, A., Morini, S., Miserocchi, A., Bon, I., & Re, M. C. (2012) · PubMed · Cited by 13
C-Reactive Protein as an Independent Cardiovascular Risk Predictor in HIV+ Patients: A Focused Review of Published Studies
Gilotra, T. S., & Geraci, S. A. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3154w · Cited by 13
HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health
Casper, C., Crane, H. M., Menon, M. P., & Money, D. (2017) · Europe PMC (PubMed Central) · doi:10.1596/978-1-4648-0524-0/ch3 · Cited by 13

Authors: The DAD Study Group
Corresponding author: The DAD Study Group
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-04-26
Volume: 356
Issue: 17
Pages: 1723-1735
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa062744
OpenAlex: W1767400858
Cited by: 1,521
References: 26
Citations by year: 2026: 17 · 2025: 22 · 2024: 19 · 2023: 30 · 2022: 30 · 2021: 45 · 2020: 39 · 2019: 49 · 2018: 64 · 2017: 51 · 2016: 81 · 2015: 92 · 2014: 87 · 2013: 114 · 2012: 130
FWCI: 185.17
Type: journal article
Language: en
Open access: green
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Digital Access to Libraries (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Columbia Academic Commons (Columbia University)
Funders: National Institute of Allergy and Infectious Diseases (U01AI046362, U01AI042170)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: myocardial infarction, antiretroviral drugs, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, HIV infection, cardiovascular risk, dyslipidemia, serum lipids, drug exposure duration
MeSH terms: Adult, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Risk, HIV-1, HIV Infections, Incidence, Poisson Distribution, HIV Protease Inhibitors, Reverse Transcriptase Inhibitors, Observation, Anti-Retroviral Agents, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks